Tevogen Bio Holdings Inc

Tevogen Bio Holdings Inc operates with a negative equity position of -$7.63 million and a total asset base of $3.31 million, indicating a highly leveraged capital structure. The company's liquidity position is further strained by a current ratio of 0.23, suggesting limited ability to meet short-term obligations. The enterprise value to EBITDA ratio of -4.78 reflects the company's unprofitable operations and challenges in generating positive cash flows. Profitability metrics reveal a return on equity of 1.27%, which is modest given the company's negative net income of -$9.66 million. The return on assets of -2.92% indicates that the company is not effectively utilizing its assets to generate returns, a concern for investors. These metrics fall below the typical thresholds for a viable biotechnology firm, suggesting operational inefficiencies. The company's geographic and segment exposure is not explicitly detailed in the available data, but the focus on healthcare diagnostics implies a concentration in this niche area. Given the absence of segment-specific revenue breakdowns, it is unclear whether the company's operations are diversified across different diagnostic technologies or geographic regions. Looking ahead, the company is expected to continue facing financial challenges, with no clear indication of a turnaround in the near term. The negative operating and net income, coupled with a free cash flow of -$9.59 million, suggests that the company is unlikely to achieve profitability in the current fiscal year. The outlook for the next fiscal year remains uncertain without significant operational or strategic changes. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential difficulties in maintaining operations without additional financing. The low dilution risk is attributed to the absence of significant dilution sources in the current financial structure. Recent events, including the latest financial filings, indicate a continued reliance on external financing to sustain operations. The company's ESG scores, particularly the governance pillar at 5.75, suggest room for improvement in corporate governance practices. The ESG controversies score of 100.00 indicates no recent controversies, which is a positive sign for the company's reputation.